The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Influence of comorbidity and ECOG on efficacy and safety in irinotecan-refractory elderly patients (>65 years) with metastatic colorectal cancer (mCRC) treated with cetuximab plus irinotecan.
Christian Jehn
No relevant relationships to disclose
L. Böning
No relevant relationships to disclose
Hendrik Kröning
No relevant relationships to disclose
Kurt Possinger
No relevant relationships to disclose
Antonio Pezzutto
No relevant relationships to disclose
Diana Lueftner
No relevant relationships to disclose